News

Protara Therapeutics Highlights Choline Deficiency Study Results

Protara Therapeutics Highlights Choline Deficiency Study Results

Protara Therapeutics Shares Findings from THRIVE-1 Study

Protara Therapeutics, Inc. (Nasdaq: TARA) has recently revealed important results from their THRIVE-1 study, aimed at addressing significant health issues. This prospective observational study examined the prevalence of choline deficiency and liver injury in patients who depend on parenteral support (PS). The findings were presented at the European Society for Clinical Nutrition and Metabolism Congress.

Study Results Highlight Choline Deficiency Issues

The study revealed that an alarming 78% of participants relying on parenteral support were found to be deficient in choline. Furthermore, 63% of these individuals showed signs of liver dysfunction, which included conditions like steatosis, cholestasis, and hepatobiliary injury. These findings emphasize the urgent need for intravenous (IV) choline supplementation for this at-risk population.

The Importance of IV Choline Chloride

Protara Therapeutics is leading the charge in developing IV Choline Chloride, an investigational therapy aimed at fulfilling this critical unmet medical need. Choline is vital for maintaining liver health, and a deficiency can result in severe complications, including liver injury and various neuropsychological disorders.

Expert Opinions and Future Directions

Dr. Palle Bekker Jeppesen, a Clinical Professor with expertise in intestinal failure and liver diseases, commented on the study's findings, noting that many patients who rely on parenteral support could greatly benefit from IV Choline Chloride. The potential for an IV formulation is particularly crucial for those unable to obtain sufficient choline through oral or enteral nutrition.

Protara's Commitment and Upcoming Initiatives

Jesse Shefferman, CEO of Protara Therapeutics, expressed the company's commitment to launching the first approved IV choline product, especially in light of the current lack of available options. Protara plans to start a pivotal pharmacokinetic trial for IV Choline Chloride in early 2025.

Overview of the THRIVE-1 Study

The THRIVE-1 study was thorough, involving 78 patients with intestinal failure who depend on parenteral support. The results highlight a significant health gap, indicating a pressing need for choline supplementation in these individuals.

Understanding IV Choline Chloride

IV Choline Chloride is being positioned as an innovative therapeutic solution. Approximately 80% of patients on parenteral support are choline deficient, and the introduction of this therapy could help avert serious liver damage and failure.

Implications for Patient Care

This investigation comes at a crucial time, addressing a major gap in the care of patients on parenteral support, who number around 40,000 in the U.S. alone. The implications of these findings could transform how healthcare providers develop treatment strategies for these patients.

About Protara Therapeutics, Inc.

Protara is committed to improving treatment options for individuals facing cancer and rare diseases. With a varied portfolio, their lead candidate, TARA-002, signifies a notable advancement in treating specific cancer types. The company remains dedicated to ensuring that patients receive the essential therapies they need.

Frequently Asked Questions

What were the key findings of the THRIVE-1 study?

The study found that 78% of patients on parenteral support were choline deficient, with 63% of those experiencing liver dysfunction.

What is IV Choline Chloride?

IV Choline Chloride is an investigational therapy aimed at providing choline supplementation to patients unable to meet their needs through oral or enteral means.

How does choline deficiency affect patients?

Choline deficiency can lead to severe health issues, including liver injuries, neuropsychological impairments, and other complications.

Why is there a need for IV Choline products?

There are currently no approved IV choline products worldwide for parenteral support patients, despite medical recommendations advocating for choline treatment.

What are Protara's future plans?

Protara is planning to initiate a pivotal trial for IV Choline Chloride in early 2025, aiming to bring the first approved formulation to market.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Caliway's China Clearance Speeds CBL-514's Next Test

Updated Category News Views 158

China's regulator moved faster than the calendar, and that is the one detail worth circling in red ink. Caliway Biopharmaceuticals has received authorization from the Center for Drug Evaluation under China's National Medical Products Administration to begin CBL-0102, its China study of injectable fat-reduction candidate CBL-514. For a clinical-stage company, an...

Continue Reading
Cybersecurity's AI Tailwind Meets a Brutal Market Test

Updated Category News Views 89

Security software caught a bid while the rest of the tape was getting kicked down the stairs. That contrast is the whole story: investors saw Palo Alto Networks deliver a strong fiscal first quarter and raise its fiscal 2027 outlook, then decided cyber defense may be one of the few technology budgets companies cannot casually postpone. With AI helping attackers locate and...

Continue Reading
IT Tech Packaging's Going-Concern Warning Lands Hard

Updated Category News Views 91

A paper maker can survive plenty of ugly quarters; it cannot casually shrug off an auditor questioning whether it can keep operating. That is the cold part of IT Tech Packaging's Nov. 19 disclosure. Its newly filed Form 10-K for the year ended Dec. 31, 2025 carries a “Material Uncertainty Related to Going Concern” paragraph from Audit Alliance LLP. Nobody should dress...

Continue Reading
AltaPointe PATH Outreach Puts Housing Waits in Focus

Updated Category News Views 128

Two years is a brutal length of time to ask somebody without stable housing to wait for an income-based apartment. That number hangs over AltaPointe Health's PATH program in Mobile, Alabama, and it ought to. The organization helped 16 people secure permanent housing in the past fiscal year, a figure that can look small if somebody is just skimming a report. It looks very...

Continue Reading
AT&T's Dec. 8 UBS Chat Puts Stankey's Updates on Watch

Updated Category News Views 202

A Small Slot With a Big Audience A calendar entry can still matter when the man holding the microphone runs AT&T. John Stankey, AT&T chairman and chief executive, is scheduled for a fireside chat at the UBS Global Media and Communications Conference on Tuesday, Dec. 8, beginning at 8:15 a.m. Eastern time. The company says the event will be webcast live through its...

Continue Reading
BET's HBCU Basketball Bet Is Bigger Than Six Games

Updated Category News Views 46

December television usually hands the microphone to the same old basketball machinery, which makes BET putting HBCU hoops in primetime feel overdue rather than merely promotional. Beginning December 3 at 8:00 p.m. ET, BET and Straight Shooter Media will air a six-game series built around Howard University and a rotating slate of opponents. The opener is Grambling State...

Continue Reading
Flair's New Aviation Alliance Offers Options, Not Orders

Updated Category News Views 0

Aircraft shortages have a funny way of turning vague partnerships into very useful insurance policies. Flair Airlines, Phoenix Aviation Capital and Avia Solutions Group announced a Strategic Commercial Cooperation Agreement on Nov. 19, 2026, and the sensible reading is straightforward: the Canadian value carrier wants more ways to solve capacity and operational problems...

Continue Reading
Story Cannabis Bets on Neighborly Thanksgiving Outreach

Updated Category News Views 39

A frozen turkey is not a grand strategy deck, thank goodness; it is dinner for a household that might be feeling the squeeze. Story Cannabis plans to hand out 840 of them on Tuesday, Nov. 24, splitting the giveaway between Columbus and Cleveland with former Ohio State and Dallas Cowboys running back Michael Wiley joining employees and volunteers. In a cannabis business...

Continue Reading
PinnacleQM Makes Its Enterprise Case More Visible

Updated Category News Views 118

Six pages were never going to carry the weight of a complicated enterprise pitch. PinnacleQM has rebuilt its public face from a basic brochure into a library of more than 50 pages, putting its quality engineering, testing, automation and AI assurance work in clearer view for Australian technology and business buyers. This is not the sort of announcement that changes a...

Continue Reading
Label-Free Detection Has a Solid, Narrow Growth Lane

Updated Category News Views 77

Biologics labs are turning into a far better hunting ground for analytical equipment than the old, broad-brush research story suggests. Label-free detection is not a giant market, and nobody should dress it up as one. But the projected move from $0.58 billion in 2026 to $0.85 billion by 2031 points to a useful 8.1% annual growth lane, driven by work researchers genuinely...

Continue Reading

Top 5 Most Recently Viewed Articles

BD Settles SEC Investigation While Strengthening Operations

Updated Category News Views 215

BD Reaches Settlement with the SEC BD (Becton, Dickinson and Company) (NYSE: BDX), a renowned leader in medical technology, has announced a significant agreement to resolve an investigation by the U.S. Securities and Exchange Commission (SEC). This follows concerns regarding prior public disclosures related to the BD Alaris™ System. Key Details of the Resolution The...

Continue Reading
Seizing the Managed Detection and Response Market Opportunity

Updated Category News Views 232

Unlocking the Managed Detection and Response Market Potential Middleton, Massachusetts – QKS Group, a leading market intelligence and advisory firm, recently released an insightful report on the global Managed Detection and Response (MDR) Market. This comprehensive analysis targets industry leaders eager to tap into a rapidly growing sector. According to their findings,...

Continue Reading
Expanding Horizons: Coldwell Banker's Venture into Africa

Updated Category News Views 94

Coldwell Banker Real Estate's New Milestone Coldwell Banker Tanzania and Zanzibar have officially joined the growing network of Coldwell Banker Real Estate LLC, marking an exciting expansion into Africa. This new master franchise embodies the brand’s ongoing commitment to deliver top-tier real estate services on an international scale. Seizing Growing Markets The real...

Continue Reading
Automotive Grade Linux Unveils SoDeV Platform for Advancements

Updated Category News Views 289

Automotive Grade Linux Introduces SoDeV for Software Defined Vehicles In an exciting development for the automotive industry, Automotive Grade Linux (AGL) has launched SoDeV, an open-source reference platform aimed at significantly enhancing the development of Software Defined Vehicles (SDVs). This innovative platform allows developers to focus on software-first...

Continue Reading
Exploring Promising Tech Stocks Ahead of Future Opportunities

Updated Category News Views 257

Opportunity in Oversold Tech Stocks The information technology sector is witnessing a notable shift, with several stocks currently considered undervalued. These oversold stocks represent potential opportunities for savvy investors looking to capitalize on future growth. By focusing on these stocks, investors can identify undervalued companies that have the potential for...

Continue Reading